In a nutshell This study aimed to determine whether androgen deprivation therapy (ADT) is associated with an increased risk of depression for patients with prostate cancer. It found that there was an increased risk of depression. Some background A main treatment option for prostate cancer is androgen deprivation therapy (ADT). This blocks...
Read More
In a nutshell The authors aimed to determine a patient’s ability to reach orgasm after robot-assisted laparoscopic prostatectomy (RALP) based on demographics, cancer-related and surgical variables, and erectile aids. The authors concluded that men could reach orgasm an average of 3 years after RALP. Poor orgasmic ability was associated with men...
Read More
In a nutshell The authors aimed to determine whether cabazitaxel (Jevtana) was superior to docetaxel (Taxotere) in improving overall survival in patients with advanced, hormone-resistant prostate cancer who had not received previous treatment with chemotherapy. The authors concluded that cabazitaxel was not superior...
Read MoreIn a nutshell The aim of this study is to determine the benefit of a combination of treatments (chemotherapy, radiation therapy, and hormone therapy) in men with oligometastatic prostate cancer after prostate surgery (surgical removal of the prostate gland). The main outcome to be measured is the safety of this combination. The details...
Read More
In a nutshell The aim of this trial is to determine the effect of the hormone therapy apalutamide (ARN-509) with or without abiraterone acetate (Zytiga), GnRH agonists or prednisone and whether they improve prostate surgery outcomes in men with high-risk prostate cancer. The outcomes to be measured include erectile function, continence, and effect on...
Read More
In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...
Read More
In a nutshell The aim of this trial is to determine how patients with advanced, hormone-resistant prostate cancer with evidence of a homologous recombination gene deficiency respond to rucaparib (Rubraca) treatment. The main outcome to be measured is the response to treatment, and changes to prostate-specific antigen levels (a protein present in...
Read More
Because of its lowly role in the human body, we think about our bladders only when something is going wrong or when we have to go really, really badly. So, November has been set aside as Bladder Health Awareness month. Here is a short review of bladder anatomy and function as well as common problems that can happen. Your bladder is connected to your...
Read More
In a nutshell The authors aimed to determine patient outcomes following partial gland ablation compared to robot-assisted radical prostate surgery in men with low- and intermediate- risk prostate cancer. The authors concluded that men with cancer confined to the prostate benefited from partial gland ablation, as it was more successful with fewer side...
Read More
In July 2017, the American Society of Clinical Oncology (ASCO) conducted the National Cancer Opinion Survey to find out what people in the US know about cancer. ASCO released the results in October. The findings have already influenced recommendations made by the organization. Beliefs About Cancer Risk Among other questions, the survey asked 4,016...
Read More
In It’s All In Your Gut, A High Fiber Diet and the Immune System, we introduced the microbiome that lives in our body. It helps with our digestion and makes the short-chained fatty acids (SCFAs) that are important to our immune system. Now several recent studies are looking at bacteria in the bodies of people with cancer. Specifically, these...
Read More
In a nutshell This study aimed to determine which patients benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination. Some background A main treatment option for prostate cancer is androgen deprivation...
Read More
